ADIS stands for “Early Diagnosis of Alzheimer’s Disease by Immune Profiling of Cytotoxic Lymphocytes and Recording of Sleep Disturbances”. The research project brings together EU-leading expertise in data science, biotechnology, clinical research as well as public involvement.
As the title already highlights, the partners aim to advance research into one of the most challenging conditions, Alzheimer’s disease.
ADIS will leverage cutting edge science and technology in conjunction with long lasting clinical expertise to provide candidate biomarkers for earlier diagnosis of Alzheimer’s disease. An earlier diagnosis means that treatments slowing down symptom worsening would have higher success chance in the future and that patients could better plan their life. I am very enthusiastic about the motivation and energy of the entire consortium to reach our ambitious goals and really looking forward to the upcoming three years of working together.
Coming soon.